Navigation Links
Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study
Date:10/4/2011

VALENCIA, Calif., Oct. 4, 2011 /PRNewswire/ -- Bioness Inc. today announced that the company has completed the initial enrollment phase of the FASTEST study to further examine the impact of its NESS L300 wireless neurostimulation technology on individuals with foot drop as a result of stroke. The FASTEST study aims to demonstrate the superiority of the NESS L300® Foot Drop System over standard therapy with an ankle-foot orthosis (AFO), and has enrolled 176 patients at 11 U.S. centers.

The NESS L300 provides an electrical stimulus to the muscles of the lower leg in order to help lift the foot up while walking. The system was cleared by the FDA in 2006, and received CE Mark from the European Union in 2007. The NESS L300 is currently available in rehabilitation centers across the country, and for home use by individuals suffering from foot drop as the result of neurological conditions including stroke, multiple sclerosis (MS), traumatic brain injury (TBI) and spinal cord injury (SCI).

Patients enrolled in the study receive rehabilitation therapy with either the NESS L300 or an AFO, and will be followed for six months and evaluated based on gait function, stroke-specific quality of life and safety.

"We are pleased to have reached this milestone and are greatly appreciative of the commitment and support of our clinical partners in reaching this goal," said Thomas Fogarty, President of Bioness Inc. "We look forward to seeing the outcome of this study and further quantifying the impact of this important technology for those who need it most."

About Bioness Inc.

Bioness provides neuromodulation technologies that help improve lives and restore function for those living with neurological deficits and peripheral pain. The Company markets innovative neuromodulation products that help individuals with central nervous system disorders such as stroke, multiple sclerosis, spinal cord injury and traumatic brain injury regain movement in affected limbs. The NESS L300® Foot Drop System and NESS H200® Hand Rehabilitation System, NESS L300® Plus System and NESS H200® Wireless Hand Rehabilitation System are cleared for use by the Food and Drug Administration and are designed to help patients achieve new levels of physical independence and productivity.

Individual results vary. Consult with a qualified physician to find out if these products are right for you. Additional information about Bioness can be found at www.bioness.com.  

Media Contact:
Wendy Ryan/Courtney Conery
Schwartz MSL
781-684-0770
bioness@schwartzmsl.com


'/>"/>
SOURCE Bioness Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioness Inc. Receives FDA Clearance of Its NESS L300 Plus System
2. Bioness Inc Announces Availability of L300 Plus System
3. Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
Breaking Medicine News(10 mins):